Literature DB >> 18298661

MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation--relevance in a mouse model of Parkinson's disease.

Tobias Thomas1, Marco Timmer, Konstantin Cesnulevicius, Edward Hitti, Alexey Kotlyarov, Matthias Gaestel.   

Abstract

The inflammatory response in the brain is closely associated with the pathogenesis of degenerative neurological disorders. A role for the p38 stress-activated protein kinase/MAPK-activated protein kinase 2 (MK2) axis in inflammation and apoptosis is well documented. Here, we provide evidence that neurodegeneration can be prevented by eliminating MK2. In primary mesencephalic neuron-glia co-cultures dopaminergic neurons from MK2-deficient (MK2-/-) mice were significantly more resistant to lipopolysaccharide-induced neurotoxicity compared with cells from wild-type mice. This neuroprotection in MK2-deficient cultures was associated with a reduced inflammatory response, especially with reduced production of the inflammatory mediators tumor necrosis factor alpha, keratinocyte-derived chemokine, interleukin-6, and nitric oxide (NO). Interestingly, in primary neuron-enriched cell cultures p38 MAPK, but not MK2, also participates in NO-mediated neuronal cell death. In the MPTP mouse model for Parkinson's disease, MK2-deficient mice show a reduced neuroinflammation and less degeneration of dopaminergic neurons in the substantia nigra after MPTP lesion compared with wild-type mice. In conclusion, our results reveal that MK2 does not directly participate in neuronal cell death, but indirectly contributes to neurodegeneration by the production of neurotoxic substances, such as NO or tumor necrosis factor alpha, from activated glia cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18298661     DOI: 10.1111/j.1471-4159.2008.05310.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  22 in total

1.  The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS.

Authors:  Adam D Bachstetter; Linda J Van Eldik
Journal:  Aging Dis       Date:  2010-09-24       Impact factor: 6.745

2.  Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions.

Authors:  Brian C Ward; Sandra Kavalukas; Jamie Brugnano; Adrian Barbul; Alyssa Panitch
Journal:  J Surg Res       Date:  2011-02-23       Impact factor: 2.192

Review 3.  p38(MAPK): stress responses from molecular mechanisms to therapeutics.

Authors:  Lydia R Coulthard; Danielle E White; Dominic L Jones; Michael F McDermott; Susan A Burchill
Journal:  Trends Mol Med       Date:  2009-08-06       Impact factor: 11.951

4.  Gene silencing of MK2 in hard-to-transfect human U937 cells.

Authors:  S M Tietz; M Berghoff
Journal:  J Biomol Tech       Date:  2012-07

Review 5.  Oxidative stress, redox signalling and endothelial dysfunction in ageing-related neurodegenerative diseases: a role of NADPH oxidase 2.

Authors:  Sarah Cahill-Smith; Jian-Mei Li
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

6.  Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo.

Authors:  Akihito Muto; Alyssa Panitch; Namho Kim; Kinam Park; Padmini Komalavilas; Colleen M Brophy; Alan Dardik
Journal:  Vascul Pharmacol       Date:  2011-10-17       Impact factor: 5.773

7.  Mitogen-activated protein kinase-activated protein kinase 2 (MK2) contributes to secondary damage after spinal cord injury.

Authors:  Nader Ghasemlou; Ruben Lopez-Vales; Claude Lachance; Thusanth Thuraisingam; Matthias Gaestel; Danuta Radzioch; Samuel David
Journal:  J Neurosci       Date:  2010-10-13       Impact factor: 6.167

8.  Mitogen-activated protein kinase-activated protein kinases 2 and 3 regulate SERCA2a expression and fiber type composition to modulate skeletal muscle and cardiomyocyte function.

Authors:  Madeleine Scharf; Stefan Neef; Robert Freund; Cornelia Geers-Knörr; Mirita Franz-Wachtel; Almuth Brandis; Dorothee Krone; Heike Schneider; Stephanie Groos; Manoj B Menon; Kin-Chow Chang; Theresia Kraft; Joachim D Meissner; Kenneth R Boheler; Lars S Maier; Matthias Gaestel; Renate J Scheibe
Journal:  Mol Cell Biol       Date:  2013-04-22       Impact factor: 4.272

9.  Novel Therapeutic Targets in Neuroinflammation and Neuropathic Pain.

Authors:  Geeta Ramesh
Journal:  Inflamm Cell Signal       Date:  2014

10.  The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury.

Authors:  Adam D Bachstetter; Rachel K Rowe; Machi Kaneko; Danielle Goulding; Jonathan Lifshitz; Linda J Van Eldik
Journal:  J Neurosci       Date:  2013-04-03       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.